Targeting Menin in T-lineage Acute Lymphoblastic Leukemia.
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
PMID: 41778833
Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors.
Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors. Haematologica. 2026 Jul 01; 111(7):2451-2456.
PMID: 41609051
Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies.
Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies. Am J Hematol. 2026 Apr; 101(4):926-929.
PMID: 41510611
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
PMID: 41139955
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025 11; 39(11):2697-2707.
PMID: 40913104
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 Aug 28; 146(9):1065-1077.
PMID: 40332046
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
PMID: 40521395
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia.
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood Cancer J. 2025 Mar 28; 15(1):49.
PMID: 40155601
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
PMID: 39133921
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 01; 43(1):75-84.
PMID: 39121437